032300 — Korea Pharma Co Income Statement

0.000.00%

Last trade - 00:00

HealthcareSpeculativeSmall CapSucker Stock

Annual income statement for Korea Pharma Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st	2025 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	79,577	81,029	83,240	81,277	87,601
Cost of Revenue
Gross Profit	35,903	35,427	36,922	35,174	31,404
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Total Operating Expenses	74,563	74,842	79,302	73,715	88,683
Operating Profit	5,014	6,187	3,939	7,562	-1,082
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	5,208	-1,780	2,014	3,906	-4,521
Provision for Income Taxes
Net Income After Taxes	6,368	-1,119	83.8	3,792	-2,640
Net Income Before Extraordinary Items
Net Income	6,368	-1,119	83.8	3,792	-2,640
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	6,368	-1,119	83.8	3,792	-2,640
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	584	-108	147	216	-231
Dividends per Share